Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Next Previous
Trial Profile

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs A2A-252 (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors A2A Pharmaceuticals

Most Recent Events

  • 27 May 2025 According to an A2A Pharmaceuticals media release, the company plans to initiate dose expansion and add prostate, gastric, sarcoma and patients with brain metastasis this summer.
  • 27 May 2025 According to an A2A Pharmaceuticals media release, a significant (22% average over approximately 2 months) tumor reduction in 67% of the 4b (BID) cohort patients was observed. This is at 160mg ,which is less than 1/3 of what we project to be to be the maximum tolerated dose as predicted by a very wide therapeutic index in pre-clinical studies. With no dose limiting toxicity and benign safety profile observed thus far, we are now at 240mg.
  • 11 Dec 2024 According to an A2A Pharmaceuticals media release, company has progressed into cohort 4, an important inflection point in its Phase 1 clinical trial to assess the safety and efficacy of its lead TACC3 inhibitor, A0-252. Early results have shown strong safety and efficacy profiles with the potential for a wide therapeutic index in these patient populations.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top